-
May 15, 2024 Lupin Achieves Significant Milestone with ISO 14001 and ISO 45001 Certification Across All its Indian Manufacturing Sites, R&D Center and Corporate Office
-
May 9, 2024 Jeffrey Kindler and Alfonso Zulueta Join Lupin Board as Independent Directors
-
May 6, 2024 Lupin Q4 FY2024 Results
-
May 6, 2024 Lupin Receives Approval from U.S. FDA for Travoprost Ophthalmic Solution USP
-
May 3, 2024 Lupin Launches Rymti® Biosimilar Etanercept in Canada
-
April 25, 2024 Lupin Receives Approval from U.S. FDA for Loteprednol Etabonate Ophthalmic Suspension, 0.5%
-
April 25, 2024 Lupin Digital Health’s Lyfe Platform Receives Class C Medical Device License from CDSCO
-
April 23, 2024 Lupin Receives EIR from U.S. FDA for its Aurangabad Manufacturing Facility
-
April 22, 2024 Lupin Launches Mirabegron Extended-Release Tablets in the United States
In this section
Media Contacts
-
Rajalakshmi Azariah
Vice President & Global Head – Corporate Communications